IKT vs MMC · $215.2M cap vs P/E 22, rev $26.98B
Inhibikase Therapeutics Inc (IKT) versus Marsh & McLennan Companies Inc (MMC) — a side-by-side from cached financials, not a winner call.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Marsh & McLennan Companies Inc (MMC) is a insurance brokers company listed on US.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
Latest reported MMC revenue for 2025-12-31 was $26.98B. Net income was $4.16B. Revenue was up 10.3% from 2024-12-31 to 2025-12-31. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
IKT currently screens at market cap $215.2M. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
Not investment advice. Open the IKT and MMC stock pages for the full models.
Not investment advice.